Results 71 to 80 of about 16,492 (195)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome

Scientific Reports
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level ...
Suzan Omar Mousa, Mohamed Farouk Afifi, Noha Anwar Hassuna, Michael Fekry Yassa, Hend Mohamed Moness   +4 more
doaj   +1 more source

Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines

Cell Reports Medicine
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.1 and Zhang et al.2 in Cell Reports Medicine and Cell Reports ...
Amirhossein Sahebkar, Maciej Banach
doaj   +1 more source

Divergent Atrial Transcriptomic Signatures in Diabetic and Nondiabetic Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 4, August 2026.
Diabetes alters the atrial transcriptome in atrial fibrillation, characterized by enhanced mitochondrial ATP synthesis, suppressed immune and inflammatory pathways, and distinct miRNA expression profiles, suggesting metabolic and epigenetic remodeling of the atrial substrate.
Kenshi Yoshimura, Yuya Kiriake, Hiroki Osanai, Mengyan Wei, Shinichiro Kume, Tatsuki Kurokawa, Masaki Morishima, Ryusuke Suzuki, Shinji Miyamoto, Katsushige Ono   +9 more
wiley   +1 more source

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)

Cancer & Metabolism, 2018
Background PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers.
Dipti Athavale, Surbhi Chouhan, Vimal Pandey, Shyamananda Singh Mayengbam, Snahlata Singh, Manoj Kumar Bhat   +5 more
doaj   +1 more source

Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Schematic overview of the proposed gut–brain axis mechanisms linking Akkermansia muciniphila to host outcomes. A. muciniphila‐derived signals, including SCFAs and P9/GLP‐1‐related endocrine pathways, may influence epithelial barrier integrity, inflammatory responses, systemic immune signaling, and neural communication through the enteric nervous system,
Amir Arsalan Ghahari, Ainur Sadykova, Salim Davlatov, Mukaddas Xusanova, Gulrukh Indiaminova, Furkat Sobirov, Mirzamakhmud Shadmanov, Umidjon Maxamatov, Patkhiddin Nishonov, Seyed Davar Siadat   +9 more
wiley   +1 more source

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP” [PDF]

Circulation, 2021
openaire   +2 more sources

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9

Атеросклероз, 2015
The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of
K. S. Astrakova, Yu. I. Ragino, E. V. Shakhtshneider, M. I. Voevoda   +3 more
doaj  

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk

South African Family Practice, 2016
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease.
Natalie Schellack, Gustav Schellack, E. Bronkhorst   +2 more
doaj   +1 more source

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong, Zaiyong Zheng, Min Huang, Shengyu Huang, Xingwei Zhao, Yang Yu, Chunxiang Zhang   +6 more
wiley   +1 more source